Treatment options in the management of necrotising fasciitis caused by Group A Streptococcus

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 8, 2004, Pages 1695-1700

  Mulla, Zuber D ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clindamycin; Necrotising fasciitis; Streptococcus pyogenes; Treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; CLINDAMYCIN; CLINDAMYCIN PHOSPHATE; ERYTHROMYCIN; IMMUNOGLOBULIN G; LEVOFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

CLINICAL FEATURE; CONSULTATION; DISEASE SEVERITY; DRUG CHOICE; EPIDEMIOLOGICAL DATA; FATALITY; HUMAN; MEDICAL SPECIALIST; MYOSITIS; NECROTIZING FASCIITIS; NONHUMAN; REVIEW; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; SURGEON;

ANTI-BACTERIAL AGENTS; FASCIITIS, NECROTIZING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PROTEIN C; RISK FACTORS; STREPTOCOCCUS PYOGENES;

EID: 4344640659     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.8.1695     Document Type: Review

References (50)

1. CENTERS FOR DISEASE CONTROL: Summary of notifiable diseases - United States, 2000. MMWR Morb. Mortal. Wkly Rep. (2002) 49(53):i-xxii, 1-100.
2. HOGE CW, SCHWARTZ B, TALKINGTON DF, BREIMAN RF, MACNEILL EM, ENGLENDER SJ: The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. JAMA (1993) 269(3):384-389.
3. KAUL R, MCGEER A, LOW DE et al.: Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Am. J. Med. (1997) 103:18-24.
4. BISNO AL, STEVENS DL: Streptococcus pyogenes. In: Mandell, Douglas and Bennett's principles and practice of infectious diseases (5th edn). Mandell GL, Bennett JE, Dolin R, (Eds), Churchill Livingstone, Inc., New York, NY, USA (2000):2101-2102.
5. TSAI P, LIN Y, KUO C et al.: Group A Streptococcus induces apoptosis in human epithelial cells. Infect. Immun. (1999) 67:4334-4339.
6. COMMITTEE ON INFECTIOUS DISEASES, AMERICAN ACADEMY OF PEDIATRICS: Group A streptococcal infections. In: Red book (25th edn). American Academy of Pediatrics, Elk Grove Village, IL, USA (2000):526-536.
7. KISKA DL, THIEDE B, CARACCIOLO, J. et al.: Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J. Infect. Dis. (1997) 176:992-1000.
8. KOTB M: Bacterial pyrogenic exotoxins as superantigens. Clin. Microbiol. Rev. (1995) 8:411-426.
9. SKOV L, BAADSGAARD O: Bacterial superantigens and inflammatory skin diseases. Clin. Exp. Dermatol. (2000) 25:57-61.
10. SCHLIEVERT PM, ASSIMACOPOULOS AP, CLEARY PP: Severe invasive group A streptococcal disease: clinical description and mechanisms of pathogenesis. J. Lab. Clin. Med. (1996) 127:13-22.
11. NADAL D, LAUENER RP, BRAEGGER CP et al.: T cell activation and cytokine release in streptococcal toxic shock-like syndrome. J. Pediatr. (1993) 122:727-729.
12. STEVENS DL, BRYANT AE, HACKETT SP et al.: Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. J. Infect. Dis. (1996) 173:619-626.
13. BASMA H, NORRBY-TEGLUND A, GUEDEZ Y et al.: Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect. Immun. (1999) 67:1871-1877.
14. STEVENS DL: Invasive group A Streptococcus infections. Clin. Infect. Dis. (1992) 14:2-11.
15. MELENEY FL: Hemolytic streptococcus gangrene. Arch. Surg. (1924) 9:317-364.
16. MULLA ZD: Invasive group A streptococcal disease and intensive care unit admissions. Intensive Care Med. (2002) 28:1822-1824.
17. WARD RG, WALSH MS: Necrotizing fasciitis: 10 years' experience in a district general hospital. Br. J. Surg. (1991) 78:488-489.
18. STEVENS DL: Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg. Infect. Dis. (1995) 1:69-78.
19. THE WORKING GROUP ON SEVERE STREPTOCOCCAL INFECTIONS: Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA (1993) 269:390-391.
20. BERNALDO DE QUIROS JCL, MORENO S, CERCENADO E et al.: Group A streptococcal bacteremia: a 10-year prospective study. Medicine (Baltimore) (1997) 76:238-248.
21. FRANCIS J, WARREN RE: Streptococcus pyogenes bacteraemia in Cambridge - a review of 67 episodes. Q.J. Med. (1988) 68:603-613.
22. KRISTENSEN B, SCHONHEYDER HC: A 13-year survey of bacteraemia due to β-haemolytic streptococci in a Danish county. J. Med. Microbiol. (1995) 43:63-67.
23. CENTERS FOR DISEASE CONTROL AND PREVENTION: Summary of notifiable diseases, United States, 1995. MMWR Morb. Mortal. Wkly Rep. (1996) 44:iii-iv.
24. O'BRIEN KL, BEALL B, BARRETT NL et al.: Epidemiology of invasive group A Streptococcus disease in the United States, 1995-1999. Clin. Infect. Dis. (2002) 35:268-276.
25. DAVIES HD, MCGEER A, SCHWARTZ B et al.: Invasive group A streptococcal infections in Ontario, Canada. N. Engl. J. Med (1996) 335:547-554.
26. ERIKSSON BKG, ANDERSSON J, HOLM SE et al.: Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin. Infect. Dis. (1998) 27:1428-1436.
27. FACTOR SH, LEVINE OS, SCHWARTZ B et al.: Invasive group A streptococcal disease: risk factors for adults. Emerg. Infect. Dis. (2003) 9:970-977.
28. CENTERS FOR DISEASE CONTROL AND PREVENTION: Outbreak of invasive group A Streptococcus associated with varicella in a childcare center - Boston, Massachusetts, 1997. MMWR Morb. Mortal. Wkly Rep. (1997) 46:944-948.
29. LAUPLAND KB, DAVIES HD, LOW DE et al.: Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Pediatrics (2000) 105:E60.
30. ZURAWSKI CA, BARDSLEY M, BEALL B et al.: Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment. Clin. Infect. Dis. (1998) 27:150-157.
31. VEENSTRA RP, MANSON WE, VAN DER WERF TS et al.: Fulminant necrotizing fasciitis and nonsteroidal anti-inflammatory drugs. Intensive Care Med. (2001) 27:1831.
32. BARNHAM MRD, WEIGHTMAN NC, ANDERSON AW, TANNA A: Streptococcal toxic shock syndrome: a description of 14 cases from North Yorkshire, UK. Clin. Microbiol. Infect. (2002) 8:174-181.
33. STEVENS DL: Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin. Infect. Dis. (1995) 21:977-980.
34. SHARKAWY A, LOW DE, SAGINUR R et al.: Severe group A streptococcal soft-tissue infections in Ontario: 1992-1996. Clin. Infect. Dis. (2002) 34:454-460.
35. MULLA ZD: Nonsteroidal anti-inflammatory drugs and hypotension among patients hospitalized for invasive group A streptococcal disease. Ann. Epidemiol. (2003) 13:543-544.
36. ARONOFF DM, BLOCH KC: Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A Streptococcus. Medicine (Baltimore) (2003) 82:225-235.
37. EAGLE H: Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infections in mice. Am. J. Med. (1952) 13:389-399.
38. STEVENS DL, GIBBONS AE, BERGSTROM R et al.: The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. (1988) 158:23-28.
39. MEDICAL ECONOMICS COMPANY, INC: Physician's desk reference (55th edn), Medical economics company, Inc., Montvale, NJ, USA (2001).
40. ZIMBELMAN J, PALMER A, TODD J: Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr. Infect. Dis. J. (1999) 18:1096-1100.
41. MULLA ZD, LEAVERTON PE, WIERSMA ST: Invasive group A streptococcal infections in Florida. South. Med. J. (2003) 96:968-973.
42. PATEL R, ROUSE MS, FLOREZ MV et al.: Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis. J. Infect. Dis. (2000) 181:230-234.
43. NORRBY-TEGLUND A, IHENDYANE N, DARENBERG J: Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand. J. Infect. Dis. (2003) 35:683-689.
44. KAUL R, MCGEER A, NORRBY-TEGLUND A et al.: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. Clin. Infect. Dis. (1999) 28:800-807.
45. MCHENRY CR, PIOTROWSKI JJ, PETRINIC D et al.: Determinants of mortality for necrotizing soft-tissue infections. Ann. Surg. (1995) 221:558-563.
46. OPAL SM: Interactions between coagulation and inflammation. Scand. Infect. Dis. (2003) 35:545-554.
47. PURNELL D, HAZLETT T, ALEXANDER SL: A new weapon against severe sepsis related to necrotizing fasciitis. Dimens. Crit. Care. Nurs. (2004) 23:18-23.
48. BISNO AL, COCKERILL FR 3rd, BERMUDEZ CT: The initial outpatient-physician encounter in group A streptococcal necrotizing fasciitis. Clin. Infect. Dis. (2000) 2:607-608.
49. DALAL M, STERNE G, MURRAY DS: Streptococcal myositis: a lesson. Br. J. Plast. Surg. (2002) 55:682-684.
50. MAJESKI JA, JOHN JF Jr: Necrotizing soft tissue infections: a guide to early diagnosis and initial therapy. South. Med. J. (2003) 96:900-905.